StockData
Molecular Partners AG logo

Molecular Partners AG (MOLN) stock

MOLNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 12, 2026Score 1/30
$2.67−0.19 (-6.82%)

Close on Nov 18, 2026Market cap $107.60MP/E –Yield –

Molecular Partners free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

For fiscal 2025 it was -CHF 51.97M. The highest annual figure on record is CHF 117.39M in fiscal 2022.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-CHF 51.97M–
FY2024Dec 31, 2024-CHF 59.95M–
FY2023Dec 31, 2023-CHF 59.58M-150.8%
FY2022Dec 31, 2022CHF 117.39M–
FY2021Dec 31, 2021-CHF 91.89M–
FY2020Dec 31, 2020-CHF 30.43M–
FY2019Dec 31, 2019-CHF 2.22M–

More Molecular Partners figures

See a number that looks wrong?